Đọc thêm Flutamide

  • Sogani PC, Whitmore WF (1988). “Flutamide and other antiandrogens in the treatment of advanced prostatic carcinoma”. Cancer Treat. Res. 39: 131–45. PMID 2908604. 
  • Brogden RN, Clissold SP (1989). “Flutamide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic cancer”. Drugs 38 (2): 185–203. PMID 2670515. doi:10.2165/00003495-198938020-00003. 
  • Neri R (1989). “Pharmacology and pharmacokinetics of flutamide”. Urology 34 (4 Suppl): 19–21; discussion 46–56. PMID 2477934. doi:10.1016/0090-4295(89)90230-6. 
  • Newling DW (1989). “The use of flutamide as monotherapy in the treatment of advanced prostate cancer”. Prog. Clin. Biol. Res. 303: 117–21. PMID 2674980. 
  • Labrie F, Dupont A, Cusan L, Manhès G, Bergeron N, Lacourcière Y, Pineault S, Bélanger A, Monfette G, Emond J (1989). “Combination therapy with castration and flutamide: today's treatment of choice for prostate cancer”. J. Steroid Biochem. 33 (4B): 817–21. PMID 2689788. 
  • Goldspiel BR, Kohler DR (1990). “Flutamide: an antiandrogen for advanced prostate cancer”. DICP 24 (6): 616–23. PMID 2193461. doi:10.1177/106002809002400612. 
  • Brogden RN, Chrisp P (1991). “Flutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in advanced prostatic cancer”. Drugs Aging 1 (2): 104–15. PMID 1794008. doi:10.2165/00002512-199101020-00003. 
  • Labrie F (1993). “Mechanism of action and pure antiandrogenic properties of flutamide”. Cancer 72 (12 Suppl): 3816–27. PMID 8252497. doi:10.1002/1097-0142(19931215)72:12+<3816::aid-cncr2820721711>3.0.co;2-3. 
  • Iversen P, Melezinek I, Schmidt A (2001). “Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function”. BJU Int. 87 (1): 47–56. PMID 11121992. doi:10.1046/j.1464-410x.2001.00988.x. 
  • Ibáñez L, de Zegher F (2006). “Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women”. Hum. Reprod. Update 12 (3): 243–52. PMID 16407452. doi:10.1093/humupd/dmi054. 
  • Brahm J, Brahm M, Segovia R, Latorre R, Zapata R, Poniachik J, Buckel E, Contreras L (2011). “Acute and fulminant hepatitis induced by flutamide: case series report and review of the literature”. Ann Hepatol 10 (1): 93–8. PMID 21301018. 
  • Giorgetti R, di Muzio M, Giorgetti A, Girolami D, Borgia L, Tagliabracci A (2017). “Flutamide-induced hepatotoxicity: ethical and scientific issues”. Eur Rev Med Pharmacol Sci 21 (1 Suppl): 69–77. PMID 28379593. 
  1. 1 2 3 4 5 6 https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d037fb0c-881f-43d2-8693-aa1342d0130a&type=display
  2. ↑
  3. 1 2 3 4
  4. ↑
  5. 1 2 James Leonard Gulley (2011). Prostate Cancer. Demos Medical Publishing. tr. 81–. ISBN 978-1-935281-91-7. 
  6. ↑ Thomas L. Lemke; David A. Williams (24 tháng 1 năm 2012). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. tr. 1373–. ISBN 978-1-60913-345-0. 
  7. ↑
  8. 1 2 3 4 5 Index Nominum 2000: International Drug Directory. Taylor & Francis. Tháng 1 năm 2000. tr. 466–. ISBN 978-3-88763-075-1. 
  9. 1 2 3 4 J. Elks (14 tháng 11 năm 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. tr. 573–. ISBN 978-1-4757-2085-3. 
  10. ↑ “Polycystic Ovary Syndrome - Treatment - NHS Choices”. Nhs.uk. 17 tháng 10 năm 2011. Truy cập ngày 4 tháng 1 năm 2013. 
  11. ↑ Ismaila A Mungadi; Hyacinth N Mbibu; Ehab Eltahawy; Abdullahi Abdulwahab-Ahmed (30 tháng 11 năm 2013). Manual of Medical Treatment in Urology. JP Medical Ltd. tr. 120–. ISBN 978-93-5090-844-0. 
  12. 1 2 Giorgetti R, di Muzio M, Giorgetti A, Girolami D, Borgia L, Tagliabracci A (2017). “Flutamide-induced hepatotoxicity: ethical and scientific issues”. Eur Rev Med Pharmacol Sci 21 (1 Suppl): 69–77. PMID 28379593. 
  13. ↑ Bennett CL, Raisch DW, Sartor O (2002). “Pneumonitis associated with nonsteroidal antiandrogens: presumptive evidence of a class effect”. Ann. Intern. Med. 137 (7): 625. PMID 12353966. doi:10.7326/0003-4819-137-7-200210010-00029. An estimated 0.77% of the 6,480 nilutamide-treated patients, 0.04% of the 41,700 flutamide-treated patients, and 0.01% of the 86,800 bicalutamide-treated patients developed pneumonitis during the study period. 
  14. ↑ Jeffrey K. Aronson (19 tháng 4 năm 2010). Meyler's Side Effects of Drugs in Cancer and Immunology. Elsevier. tr. 318–319. ISBN 978-0-08-093288-0. 
  15. ↑ McLeod DG (1997). “Tolerability of Nonsteroidal Antiandrogens in the Treatment of Advanced Prostate Cancer”. Oncologist 2 (1): 18–27. PMID 10388026. 
  16. ↑ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery (bằng tiếng Anh). John Wiley & Sons. tr. 515. ISBN 9783527607495. 
  17. ↑ Lutz Moser (1 tháng 1 năm 2008). Controversies in the Treatment of Prostate Cancer. Karger Medical and Scientific Publishers. tr. 41–42. ISBN 978-3-8055-8524-8. Latest studies suggest that [flutamide] also reduces adrenal and ovarian androgen synthesis [58,59]. [...] No alteration in the hormone levels has been observed in patients treated with flutamide for 6 or 12 months [61,62]. However in other studies flutamide decreased circulating concentrations of DHEAS as well as androstenedione, total testosterone and 3a-androstanediol glucuronide, in young women with PCOS [41,59]. These effects may be due to inhibition of adrenal 17-20 lyase [17,63]. Although there was no effect on gonadotropin response to GnRH, basal levels of FSH showed a rise associated with a small fall of LH [64]. 
  18. ↑ Stabile, R. G.; Dicks, A. P. (2003). “Microscale Synthesis and Spectroscopic Analysis of Flutamide, an Antiandrogen Prostate Cancer Drug”. Journal of Chemical Education 80 (12): 1439. doi:10.1021/ed080p1439. 
  19. ↑ Baker, J. W.; Bachman, G. L.; Schumacher, I.; Roman, D. P.; Tharp, A. L. (1967). “Synthesis and Bacteriostatic Activity of Some Nitrotrifluoro methylanilides”. Journal of Medicinal Chemistry 10 (1): 93–5. PMID 6031711. doi:10.1021/jm00313a020. 
  20. ↑ Bandgar, B. P.; Sawant, S. S. (2006). “Novel and Gram‐Scale Green Synthesis of Flutamide”. Synthetic Communications 36 (7): 859–864. doi:10.1080/00397910500464848. 
  21. 1 2 3 4 https://www.drugs.com/international/flutamide.html
  22. ↑ Vozianov AF, Reznikov AG, Varga SV (1995). “Endocrine changes underlying clinical effects of low-dose estrogen-antiandrogen treatment of prostatic cancer”. Endocrine Regulations 29 (1): 25–28. ISSN 0013-7200. 
  23. ↑ Vozianov OF, Rieznikov OH, Klymenko IO, Varga SV, Synitsyn PV, Chaĭkovs'ka LV, Vozianov SO, Arystova TI (1996). “Koreliatsiia hormonal'nykh ta klinichnykh efektiv u khvorykh na rak peredmikhurovoï zalozy pry likuvanni niftolidom u poiednanni z malymy dozamy synestrolu” [The correlation of the hormonal and clinical effects in patients with prostatic cancer undergoing niftolid treatment in combination with low doses of synestrol]. Lik. Sprava (bằng tiếng Ukrainian) (1–2): 107–10. ISSN 1019-5297. PMID 9005063.  Bảo trì CS1: Ngôn ngữ không rõ (link)
  24. ↑ Vozianov AF, Reznikov AG, Klimenko IA, Chaikovskaya LV (tháng 1 năm 1998). “Benefits of low dose estrogen-antiandrogen treatment of prostate cancer”. Naunyn-Schmiedebergs Archiv für Pharmakologie [Naunyn-Schmiedeberg's Archives of Pharmacology] 358 (1): R532. ISSN 0028-1298. 
  25. ↑ Reznikov AG, Chaikovskaya LV (tháng 1 năm 1998). “Mechanisms of potentiating effect of low dose estrogens on flutamide-induced suppression of normal and cancerous prostate”. Naunyn-Schmiedebergs Archiv für Pharmakologie [Naunyn-Schmiedeberg's Archives of Pharmacology] 358 (1): R545. ISSN 0028-1298. 
  26. ↑ Reznikov, AG, Chaikovskaya, LV, Polyakova, LI, Sachinskaya, OV, Bakhmach EV (tháng 9 năm 1999). “Effects of combined treatment with niftolide and low doses of antitumor estrogen preparation, chlorotrianizene, on rat prostate”. Eksperimentalʹnai͡a onkologii͡a [Experimental Oncology] 21 (3–4): 269–273. ISSN 0204-3564. 
  27. ↑ Oesterling JE (1994). “Endocrine therapies for symptomatic benign prostatic hyperplasia”. Urology 43 (2 Suppl): 7–16. PMID 7509536. doi:10.1016/0090-4295(94)90212-7. 
  28. ↑ Stone NN (1989). “Flutamide in treatment of benign prostatic hypertrophy”. Urology 34 (4 Suppl): 64–8; discussion 87–96. PMID 2477936. doi:10.1016/0090-4295(89)90236-7. 
  29. 1 2 Lee M, Sharifi R (1997). “Benign prostatic hyperplasia: diagnosis and treatment guideline”. Ann Pharmacother 31 (4): 481–6. PMID 9101011. doi:10.1177/106002809703100415. 
  30. 1 2 Howell A, Dodwell DJ, Anderson H (tháng 3 năm 1990). “New endocrine approaches to breast cancer”. Baillière's Clin. Endocrinol. Metab. 4 (1): 67–84. PMID 1975167. doi:10.1016/S0950-351X(05)80316-7. 
  31. 1 2 Rahim B, O'Regan R (tháng 2 năm 2017). “AR Signaling in Breast Cancer”. Cancers (Basel) 9 (3). PMC 5366816. PMID 28245550. doi:10.3390/cancers9030021. 
  32. ↑ Zhao TP, He GF (tháng 2 năm 1988). “A phase II clinical trial of flutamide in the treatment of advanced breast cancer”. Tumori 74 (1): 53–6. PMID 3354065. doi:10.1177/030089168807400109. 
  33. ↑ Perrault DJ, Logan DM, Stewart DJ, Bramwell VH, Paterson AH, Eisenhauer EA (tháng 9 năm 1988). “Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study”. Invest New Drugs 6 (3): 207–10. PMID 3192386. doi:10.1007/BF00175399. 
  34. ↑ Wu Y, Vadgama JV (tháng 4 năm 2017). “Androgen Receptor as a Potential Target for Treatment of Breast Cancer”. Int J Cancer Res Mol Mech 3 (1). PMC 5412726. PMID 28474005. doi:10.16966/2381-3318.129. 
  35. ↑ Naessén, Sabine; Hirschberg, Angelica Lindén (2011). “Sex Hormones and Appetite in Women: A Focus on Bulimia Nervosa”. tr. 1759–1767. doi:10.1007/978-0-387-92271-3_114. 
  36. ↑ McElroy SL, Guerdjikova AI, Mori N, O'Melia AM (2012). “Current pharmacotherapy options for bulimia nervosa and binge eating disorder”. Expert Opin Pharmacother 13 (14): 2015–26. PMID 22946772. doi:10.1517/14656566.2012.721781. 
  37. ↑ Bergman L, Eriksson E (1996). “Marked symptom reduction in two women with bulimia nervosa treated with the testosterone receptor antagonist flutamide”. Acta Psychiatr Scand 94 (2): 137–9. PMID 8883576. doi:10.1111/j.1600-0447.1996.tb09838.x. 
  38. ↑ Sundblad C, Landén M, Eriksson T, Bergman L, Eriksson E (2005). “Effects of the androgen antagonist flutamide and the serotonin reuptake inhibitor citalopram in bulimia nervosa: a placebo-controlled pilot study”. J Clin Psychopharmacol 25 (1): 85–8. PMID 15643104. doi:10.1097/01.jcp.0000150222.31007.a9.